about
Current translational and clinical practices in hematopoietic cell and gene therapyDesigner nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers.Reaction of Lymphoid Organs to Injection of Iron-Carbon Nanoparticles.A generic 89Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography.Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicLiposomes in tissue engineering and regenerative medicineMultifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release.Nanotechnology-based approaches in anticancer researchThe pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.Toxicity Study of Streptococcus pneumoniae Vaccine Administrated Subcutaneously in Rats.Injectable liposomal formulations of opiorphin as a new therapeutic strategy in pain management.Phototriggerable liposomes: current research and future perspectives.Pharmacogenomics-based RNA interference nanodelivery: focus on solid malignant tumors.Delivery of RNAi therapeutics: work in progress.Delivering the promise of small ncRNA therapeutics.Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.Nanotechnology applied to treatment of mucopolysaccharidoses.Histones and DNA compete for binding polyphosphoinositides in bilayersReceptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.Multimodal cancer treatment: real time monitoring, optimization, and synergistic effects.Potential antitumor activity of novel DODAC/PHO-S liposomesEffect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation.CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.High-Throughput Continuous Flow Production of Nanoscale Liposomes by Microfluidic Vertical Flow Focusing.Cancer Nanotechnology: Opportunities for Prevention, Diagnosis, and Therapy.Nuclisome--targeting the tumor cell nucleus.
P2860
Q27024456-A354F9A9-2D02-427C-AD62-9B35BCD96249Q30476027-E837B032-7126-4DF4-A356-DCCAF8128F53Q33437262-B2571E92-3F14-461F-AB05-A22743EC6675Q33601723-A66E22FA-CAA7-4EAF-9910-C425003A9630Q33715708-FCE50BD1-01DE-478E-AAE5-B966946F7301Q33911056-14DE16F1-9EEA-4091-AE50-C7E133C92F94Q34470412-4A5F7DAD-FEEB-4821-A178-688394101F66Q35688089-912017CC-631C-4F57-917E-90F19324C04BQ36168983-6976AA2F-4812-428C-B080-FD8C608629EAQ36191605-F83C1BDB-C04A-4E24-BB22-7C4CA43A1592Q36234343-1E40C499-84BC-49B6-A92E-610FDC596A7DQ36998357-F17A7567-6243-4084-89EC-E7A04813676DQ37326244-B091E0A9-9D3A-4E44-9068-875C035ACAFFQ37474355-9C7D994B-A58B-43A3-9330-9CD51FF39C87Q37689852-7708979D-B009-4809-ABBA-302E5DFFE661Q38015528-0BF66212-EEE9-4C26-96AB-02652C4B3808Q38160246-19F42ED1-E590-4A0E-82B4-2AC2A34BC485Q38226666-A8EC030A-8A94-4048-9233-A56BE7F416ABQ38494691-6502D47A-1EA1-4E75-A7F7-87437EA71F1CQ38850942-6032E084-850F-498A-938D-3EFB1126B575Q39759894-CF30072A-AFF2-44DF-B26D-DEB642638C1FQ39819856-9B1B7EC8-2602-4C77-8F37-E9B1392188E9Q39941336-78CCAC7F-CA40-41AE-B427-22F53EE7533AQ40510633-6BF95531-8742-4CDD-B71C-0B1338F3CE6AQ42593696-EB0D7B44-55C7-4F3B-8F27-1CDD1A438C47Q45293948-D8D94332-F447-4AE4-B648-AD4907036E17Q51481558-B7C8425A-824A-4050-95CD-F5B1C016AC6BQ53533429-BD7E6D44-8C5B-43B9-9A66-45C250A49CC4Q54532261-1D757B3C-62D4-42C0-A3FD-DC652A5987CD
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Liposomal nanomedicines: an emerging field.
@en
Liposomal nanomedicines: an emerging field.
@nl
type
label
Liposomal nanomedicines: an emerging field.
@en
Liposomal nanomedicines: an emerging field.
@nl
prefLabel
Liposomal nanomedicines: an emerging field.
@en
Liposomal nanomedicines: an emerging field.
@nl
P2093
P2860
P356
P1476
Liposomal nanomedicines: an emerging field.
@en
P2093
Arcadio Chonn
David B Fenske
Pieter R Cullis
P2860
P356
10.1177/0192623307310960
P407
P577
2008-01-01T00:00:00Z